Safety of disease modifying anti-rheumatic agents in rheumatoid arthritis patients with chronic viral hepatitis

Clinical and Experimental Rheumatology

Volumn 18, Issue 3, 2000, Pages 363-368

  Mok, M Y ^a   Ng, W L ^b   Yuen, M F ^a   Wong, R W S ^a   Lau, C S ^a  

^a QUEEN MARY HOSPITAL   (Hong Kong)

^b UNITED CHRISTIAN HOSPITAL   (Hong Kong)

Author keywords

Disease modifying drugs; Hepatitis B virus; Hepatitis C virus; Hepatotoxicity

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTIRHEUMATIC AGENT; AZATHIOPRINE; GOLD; HYDROXYCHLOROQUINE; METHOTREXATE; PENICILLAMINE; SALAZOSULFAPYRIDINE;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CHRONIC HEPATITIS; CLINICAL ARTICLE; COMORBIDITY; CONTROLLED STUDY; DRUG INDUCED DISEASE; DRUG SAFETY; FEMALE; HEPATITIS B; HUMAN; LIVER TOXICITY; MALE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; VIRUS REACTIVATION;

ADULT; AGED; ALANINE TRANSAMINASE; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; FEMALE; HEPATITIS B, CHRONIC; HEPATITIS C, CHRONIC; HEPATITIS, TOXIC; HUMANS; LIVER; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES;

EID: 0034047941     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. LOK AS, LAI CL, WU PC: Prevalence of isolated antibody to hepatitis B core antigen in an area endemic for hepatitis B virus infection: Implications in hepatitis B vaccination programs. Hepatology 1988; 8: 766-70.
2. VAN DER HEIJDE A, JACOBS JW, BIJLSMA JW et al.: The effectiveness of early treatment with "second line" antirheumatic drugs. A randomized, controlled trial. Ann Intern Med 1996; 24: 699-707.
3. WILSKE KR: Inverting the therapeutic pyramid: observations and recommendations on new directions in rheumatoid arthritis therapy based upon the author's experience. Semin Arthritis Rheum 1993; 23: 11-8.
4. WEINBLATT ME: Rheumatoid arthritis: Treat now, not later. Ann Intern Med 1996; 124: 773-4.
5. ROENIGK HH JR, AUERBACH R, MAIBACH HI, WEINSTEIN GD: Methotrexate guidelines: revised. J Am Acad Dermatol 1982; 6: 145-55.
6. WONG VC, IP HM, REESINK HW et al.: Prevention of the HBsAg carrier state in newborn infants of mothers who are chronic carriers of HBsAg and HBeAg by administration of hepatitis-B vaccine and hepatitis-B immunoglobulin. Double-blind randomised placebo-controlled study. Lancet 1984; 28: 921-6.
7. DE LA MONTE SM, HUTCHINS GM, MOORE GW: Risk factors for development of lethal sequelae after hepatitis B virus infection in humans. AmJ Med 1984; 77: 482-8.
8. KREMER JM, ALARCON GS, LIGHTFOOT RW JR et at.: Methotrexate for rheumatoid arthritis: Suggested guidelines for monitoring liver toxicitiy. Arthritis Rheum 1994; 7: 316-28.
9. WEINBLATT ME, KAPLAN H, GERMAIN BF et al.: Methotrexate in rheumatoid arthritis: A five-year prospective multicenter study. Arthritis Rheum 1995; 37: 1492-8.
10. GALBRAITH RM, EDDLESTON AL, WILLIAM R, ZUCKERMAN AJ: Fulminant hepatic failure in leukaemia and choriocarcinoma related to withdrawal of cytotoxic drug therapy. Lancet 1975; 20: 528-30.